Australia Paroxysmal Noctural Hemglobinuria (PNH) Therapeutics Market Analysis

Australia Paroxysmal Noctural Hemglobinuria (PNH) Therapeutics Market Analysis


$ 3999

Australia Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The market for Paroxysmal Nocturnal Hemoglobinuria Therapeutics is being driven by reasons like the rise in blood and bone marrow abnormalities, population ageing, rising disposable income, unmet demand for PNH treatment, and technological improvements in stem cell transplantation. Major global players in Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market are Achillion Pharmaceuticals Akari Therapeutics Alexion Pharmaceuticals Amgen Inc. Apellis Pharmaceuticals F. Hoffmann-La Roche AG. GE Healthcare Johnson & Johnson Ra Pharmaceuticals Regeneron Pharmaceuticals, Inc. Takeda Pharmaceutical Company Limited (Shire Plc) Thermo Fisher Scientific Inc.

ID: IN10AURD057 CATEGORY: Rare Diseases GEOGRAPHY: Australia AUTHOR: Sakshi Mantri

Buy Now

Australia Paroxysmal Noctural Hemglobinuria (PNH) Therapeutics Market Analysis Summary

Australia Paroxysmal Noctural Hemglobinuria (PNH) Therapeutics Market is valued at around $33.6 Mn in 2022 and is projected to reach $99.96 Mn by 2030, exhibiting a CAGR of 14.6% during the forecast period 2023-2030.

20,000 people worldwide suffer from PNH, a relatively rare chronic blood disorder. The three main symptoms of this potentially fatal acquired disease are thrombosis, pancytopenia, and persistent intravascular hemolysis. About 10,000 PNH cases have been reported in North America and Europe, with a PNH incidence of above 1.3 cases per million each year. PNH can present with a variety of symptoms that can be confused with those of other illnesses. Typical symptoms include bruising or bleeding, as well as weakness and exhaustion. Many different illnesses can show PNH symptoms, but you can avoid potentially fatal consequences with early detection and efficient treatment.

The market for Paroxysmal Nocturnal Hemoglobinuria Therapeutics is being driven by reasons like the rise in blood and bone marrow abnormalities, population ageing, rising disposable income, unmet demand for PNH treatment, and technological improvements in stem cell transplantation. Major global players in Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market are Achillion Pharmaceuticals Akari Therapeutics Alexion Pharmaceuticals Amgen Inc. Apellis Pharmaceuticals F. Hoffmann-La Roche AG. GE Healthcare Johnson & Johnson Ra Pharmaceuticals Regeneron Pharmaceuticals, Inc. Takeda Pharmaceutical Company Limited (Shire Plc) Thermo Fisher Scientific Inc.

Market Dynamics

Market Drivers

  • The market is expanding as a result of the rise in blood disease prevalence. Biologics that aim to treat the underlying causes of hemolytic abnormalities or aberrant hematopoietic stem cells are projected to stimulate market expansion.
  • The large unmet demand for pharmaceuticals in developing countries is another factor driving market growth.
  • Increased government, public, and private organization investment in the development of novel medications is leading to market expansion.

Market Restraints

  • The high expense of prescription drugs and surgical treatments like stem cell transplants restricts market growth (SCT).
  • Unfavourable side effects of current therapies may restrict market growth.
  • The unfavourable reimbursement environment in emerging nations is impeding the market's development. Growth in the bone marrow transplant market is being constrained by its risks.

Key players

Alexion Pharmaceuticals Pfizer Sanofi Catalyst Biosciences uniQure Ionis Pharmaceuticals Alnylam Pharmaceuticals Intercept Pharmaceuticals Novartis Roche

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Market Segmentations For Australia Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market

By Treatment

  • Medication
  • Supplements
  • blood transfusion
  • bone marrow transplant

By Drugs

  • Eculizumab
  • Ravulizumab
  • others

By End User

  • Hospitals
  • Homecare
  • Speciality centres
  • others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.​

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

  • Analyzing historical proprietary data collected from multiple projects.
  • Regularly updating our existing data sets with new findings and trends.
  • Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

  • Searching through academic conferences, published research, citations, and social media platforms
  • Collecting and compiling diverse data to build a comprehensive and detailed database
  • Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

  • Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
  • Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
  • Continuously refreshing our database to ensure that the information remains current and reliable.
  • Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

  • Merging historical data from secondary research with real-time data from primary research.
  • Conducting thorough data validation and cleansing to remove inconsistencies and errors.
  • Organizing data into a structured format that is easily accessible and usable for various applications.
  • Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


Last updated on: 04 July 2023
Updated by: Dr. Purav Gandhi

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up